(2-Bromoethoxy)-tert-butyldimethylsilane → N-(1-((1-(2-(tert-butyldimethylsilyloxy)ethyl)-1H-pyrazol-4-yl)methyl)-3-ethyl-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide

HRID 79314

反応式

HRID 79314 の反応式
[NH:1]1[CH:5]=[C:4]([CH2:6][N:7]2[C:15]3[C:10](=[C:11]([NH:16][C:17]([C:19]4[N:23]5[CH:24]=[CH:25][CH:26]=[CH:27][C:22]5=[N:21][CH:20]=4)=[O:18])[CH:12]=[CH:13][CH:14]=3)[C:9]([CH2:28][CH3:29])=[N:8]2)[CH:3]=[N:2]1.Br[CH2:31][CH2:32][O:33][Si:34]([C:37]([CH3:40])([CH3:39])[CH3:38])([CH3:36])[CH3:35].O.[OH-].[Cs+]>CN(C=O)C>[Si:34]([O:33][CH2:32][CH2:31][N:1]1[CH:5]=[C:4]([CH2:6][N:7]2[C:15]3[C:10](=[C:11]([NH:16][C:17]([C:19]4[N:23]5[CH:24]=[CH:25][CH:26]=[CH:27][C:22]5=[N:21][CH:20]=4)=[O:18])[CH:12]=[CH:13][CH:14]=3)[C:9]([CH2:28][CH3:29])=[N:8]2)[CH:3]=[N:2]1)([C:37]([CH3:40])([CH3:39])[CH3:38])([CH3:36])[CH3:35]

参加物

5

反応物 3

HCID 3608067(2-Bromoethoxy)-tert-butyldimethylsilaneHCID 23679066Caesium hydroxide--water (1/1/1)HCID 67259648N-(1-((1H-pyrazol-4-yl)methyl)-3-ethyl-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide

生成物 1

HCID 70814928N-(1-((1-(2-(tert-butyldimethylsilyloxy)ethyl)-1H-pyrazol-4-yl)methyl)-3-ethyl-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide収率 56.6%

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

実験手順

To N-(1-((1H-pyrazol-4-yl)methyl)-3-ethyl-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (20 mg, 0.052 mmol) in DMF (5 mL) was added (2-bromoethoxy)(tert-butyl)dimethylsilane (37 mg, 0.16 mmol), cesium hydroxide hydrate (17 mg, 0.10 mmol) and 4 angstrom molecular sieves (2 g). The reaction mixture was stirred for 3 hours and then concentrated. Purification by silica gel chromatography (DCM/MeOH 10:1) gave the desired product (16 mg).

後処理

  1. concentrationconcentrated
  2. customPurification by silica gel chromatography (DCM/MeOH 10:1)

出典と根拠

ORDレコード
ord-775cfd77318c437fa01462f6fcd3da16
出典データセット
uspto-grants-2014_09
特許番号
US08841455B2

関連ノート

読み込み中…